DNAStar signs agreement with Cancer Research UK
20 November 2006Tweet
Bioinformatics company DNAStar has signed a site license agreement with GATC Biotech and Cancer Research UK, that allows Cancer Research UK to use the current version of DNAStar’s Lasergene software anywhere on its Lincoln’s Inn Fields or Clare Hall campuses for a three-year period. In addition, researchers at other sites are entitled to special terms to purchase Lasergene software for their research needs.
Cancer Research UK joins a growing list of organisations from over 65 countries that are using Lasergene in the assembly and analysis of DNA and protein sequences. Tom Schwei, DNAStar’s vice president and general manager, said: 'With great assistance from GATC Biotech, who work with DNAStar in the distribution of our products throughout Europe, we are gratified that Cancer Research UK chose our software for their sequence assembly and analysis research needs. We are seeing a growing trend of organisations electing to standardise their research platforms.’